GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jacobson Pharma Corp Ltd (HKSE:02633) » Definitions » Cash Ratio

Jacobson Pharma (HKSE:02633) Cash Ratio : 1.00 (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jacobson Pharma Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Jacobson Pharma's Cash Ratio for the quarter that ended in Sep. 2024 was 1.00.

Jacobson Pharma has a Cash Ratio of 1.00. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Jacobson Pharma's Cash Ratio or its related term are showing as below:

HKSE:02633' s Cash Ratio Range Over the Past 10 Years
Min: 0.1   Med: 0.59   Max: 2.24
Current: 1

During the past 11 years, Jacobson Pharma's highest Cash Ratio was 2.24. The lowest was 0.10. And the median was 0.59.

HKSE:02633's Cash Ratio is ranked better than
62.93% of 998 companies
in the Drug Manufacturers industry
Industry Median: 0.585 vs HKSE:02633: 1.00

Jacobson Pharma Cash Ratio Historical Data

The historical data trend for Jacobson Pharma's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobson Pharma Cash Ratio Chart

Jacobson Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.55 0.58 1.58 1.10

Jacobson Pharma Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 1.58 0.79 1.10 1.00

Competitive Comparison of Jacobson Pharma's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jacobson Pharma's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Jacobson Pharma's Cash Ratio falls into.


;
;

Jacobson Pharma Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Jacobson Pharma's Cash Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash Ratio (A: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=411.937/372.843
=1.10

Jacobson Pharma's Cash Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash Ratio (Q: Sep. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=515.902/516.489
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jacobson Pharma  (HKSE:02633) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Jacobson Pharma Cash Ratio Related Terms

Thank you for viewing the detailed overview of Jacobson Pharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jacobson Pharma Business Description

Traded in Other Exchanges
N/A
Address
388 Kwun Tong Road, Unit 2313-18, 23rd Floor, Tower 1, Millennium City 1, Kwun Tong, Kowloon, Hong Kong, HKG
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
Executives
Sum Kwong Yip, Derek 2305 Beneficiary of a trust
Lau Wing Hung
Kingshill Development Group Inc
Kingshill Development Limited
Ubs Trustees (b.v.i.) Limited
Queenshill Development Limited
Longjin Investments Limited
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si

Jacobson Pharma Headlines

No Headlines